Related Experiment Video
Updated: Jun 9, 2026
Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells
Published on: November 9, 2010
Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cells
Abstract:
Lethal toxins could become potent therapies against cancer, but their clinical utility is limited by adverse events upon systemic administration. These could be reduced if the toxins were delivered by effector cells that specifically infiltrate cancers, thereby releasing toxins locally into the tumor microenvironment. One of the challenges underlying this strategy is that cells delivering toxins would have to be resistant to them. We address this obstacle by showing that effectors derived from transformed human cell lines genetically engineered for resistance to bacterial adenosine diphosphate ribosylating toxins (ADPRTs), including Pseudomonas aeruginosa exotoxin A (PE), can produce targeted immunotoxins that specifically kill cancer cells expressing cognate tumor-associated antigens. Resistance to immunotoxins was achieved by knockout of genes in the diphthamide biosynthesis pathway ( DPH1-4 ) required for the posttranslational modification of eukaryotic elongation factor 2 (EEF2) that is the target of ADPRTs, or by mutation of EEF2 itself. We show that engineering resistance to ADPRTs, one of the most potent toxins acting on human cells, is essential to achieve robust function of armored effector cell lines. This work establishes a first step on the path to equip effector cells with the ability to deliver powerful toxins to cancer cells and introduces a platform to investigate extension to primary autologous or allogeneic therapeutic cell types.
Insights
Genetically engineered cells resist lethal toxins, enabling targeted cancer therapy. This breakthrough allows effector cells to deliver potent toxins directly to tumors, minimizing side effects.
Area of Science:
- Biotechnology
- Cancer Therapeutics
- Molecular Biology
Background:
- Lethal toxins show promise as cancer therapies but cause severe side effects when administered systemically.
- Targeted delivery of toxins by effector cells to the tumor microenvironment could mitigate adverse events.
- A key challenge is ensuring effector cells are resistant to the toxins they deliver.
Purpose of the Study:
- To engineer effector cells resistant to bacterial adenosine diphosphate ribosylating toxins (ADPRTs).
- To develop a platform for targeted cancer immunotoxin delivery using resistant effector cells.
- To establish a foundation for equipping therapeutic cells with potent toxin delivery capabilities.
Main Methods:
- Genetically engineered transformed human cell lines for resistance to ADPRTs, including *Pseudomonas aeruginosa* exotoxin A (PE).
- Achieved resistance via knockout of diphthamide biosynthesis pathway genes (*DPH1-4*) or mutation of eukaryotic elongation factor 2 (*EEF2*).
- Demonstrated that engineered resistance is crucial for robust effector cell function.
Main Results:
- Engineered effector cells produced targeted immunotoxins that specifically kill cancer cells expressing tumor-associated antigens.
- Resistance to ADPRTs was successfully conferred by modifying the EEF2 target.
- The armored effector cell lines demonstrated robust function, essential for therapeutic efficacy.
Conclusions:
- Engineering resistance to potent toxins like ADPRTs is vital for developing effective cancer-targeting effector cells.
- This study presents a novel platform for creating toxin-resistant therapeutic cells.
- The findings pave the way for future investigations into autologous or allogeneic therapeutic cell types for cancer treatment.
More Related Videos
11:07Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
